FDA Seeks More Data on Forest and Gedeon Richter’s Schizophrenia Drug

Washington Drug Letter
The FDA has handed Forest Laboratories and Gedeon Richter a complete response letter asking for more data on cariprazine, the companies’ drug candidate to treat schizophrenia and manic or mixed episodes of bipolar I disorder in adults.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00